Systemic inflammatory response to coronary artery bypass graft surgery

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 4, 2005, Pages

  Hess Jr , Philip J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aprotinin; Coronary artery bypass; Hemostatics; Mechanism of action

Indexed keywords

APROTININ; BRADYKININ; ELASTASE INHIBITOR; KALLIKREIN; PLASMIN; SERINE PROTEINASE; THROMBIN;

BYPASS SURGERY; CELL MIGRATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FIBRINOLYSIS; HUMAN; LEUKOCYTE COUNT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE FUNCTION; TISSUE INJURY;

EID: 24944592397     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050302     Document Type: Conference Paper

References (15)

1. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001; 71(2):745-54.
2. Cugno M, Nussberger J, Biglioli P et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest. 2001; 120(6):1776-82.
3. Harris DN, Bailey SM, Smith PL et al. Brain swelling in first hour after coronary artery bypass surgery. Lancet. 1993; 342 (8871):586-7.
4. Zausinger S, Lumenta DB, Pruneau D et al. Effects of LF 16-0687 Ms, a bradykinin B(2) receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia. Brain Res. 2002; 950(1-2):268-78.
5. Kamiya T, Katayama Y, Kashiwagi F et al. The role of bradykinin in mediating ischemic brain edema in rats. Stroke. 1993; 24(4):571-5.
6. Nagaoka H, Katori M. Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in open-heart surgery. Circulation. 1975; 52(2):325-32.
7. Wachtfogel YT, Hack CE, Nuijens JH et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol. 1995; 268(3 Pt 2):H1352-7.
8. Wachtfogel YT, Kucich U, Hack CE et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993; 106(1): 1-9.
9. Asimakopoulos G, Thompson R, Nourshargh S et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000; 120(2):361-9.
10. Durgut K, Hosgor K, Gormus N et al. The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs. Perfusion. 2004; 19(2): 101-6.
11. Hill GE, Alonso A, Spurzem JR et al. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995; 110(6):1658-62.
12. Lei Y, Haider H, Chusnsheng W et al. Dose-dependent effect of aprotinin on aggravated pro-inflammatory cytokines in patients with pulmonary hypertension following cardiopulmonary bypass. Cardiovasc Drugs Ther. 2003; 17(4):343-8.
13. Spiess BD, Royston D, Levy JH et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;44(8):1143-8.
14. Lavee J, Savion N, Smolinsky A et al. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg. 1992; 53(3):477-81.
15. Poullis M, Manning R, Laffan M et al. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2000; 120(2):370-8.